That is 40.00 % down compareed to $-0.1 earnings per share for a year ago. The stock decreased 0.85% or $0.0148 during the last trading session, hitting $1.7252.Moleculin Biotech, Inc. has volume of 11,916 shares. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.14) by $0.06. research analysts anticipate that Moleculin Biotech will post -0.57 earnings per share for the current year. After $-0.17 EPS was announced last quarter, analysts now see EPS growth of -17.65 % for Moleculin Biotech, Inc. MBRX outperformed by 59.09% the S&P500.
Moleculin Biotech, Inc., a preclinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates.The firm is valued at $45.61 million. The Company's lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia.now it has negative earnings. (NASDAQ:MBRX) news were released by Nasdaq.com, Streetinsider.com and Nasdaq.com.
Moleculin Biotech, Inc.is based in Houston, TX. The first one has "Moleculin to Begin Clinical Trials at UMC Southwest Cancer Center" as a title and was brought out on May 16, 2018. The company also develops WP1066 Portfolio, an immuno-stimulating STAT3 inhibitor for the treatment of brain tumors, pancreatic cancer, and AML; and WP1122 Portfolio and related molecules for the treatment of glioblastoma multiforme and related central nervous system malignancies. The next is "Moleculin Biotech (MBRX) Enters Pact with BSP Pharmaceuticals for its Leukemia Drug Candidate" on April 24, 2018. And last was released on May 15, 2018, called "Moleculin Biotech, Inc".
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.